Members of our executive management have played leading roles in the development and commercialization of multiple significant drugs in a wide range of therapeutic areas.
Dr. Went, founding CEO and Chairman of Adamas Pharmaceuticals, has overseen the development of the company since its inception. Previously, Dr. Went co-founded CuraGen Corporation in 1992, where he served as an Executive Vice President and Director. Dr. Went received his Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from Carnegie Mellon University. Dr. Went is the author of 28 papers and an inventor on more than 70 issued patents and pending applications.
Mr. Merriweather joined the company in June 2017. Before coming to Adamas, he was Chief Financial Officer at RainDance Technologies, Inc. Prior to RainDance, he served as Chief Financial Officer of Verinata Health, Inc. and before that as Chief Financial Officer of Celera Corporation. Mr. Merriweather previously spent over 25 years in senior financial positions at several private and public life science companies, including Monogram Biosciences, Inc. and Laserscope. Mr. Merriweather received a Bachelor’s degree from the University of Cambridge in the United Kingdom.
Mr. King joined the company in April 2017. Before coming to Adamas, Mr. King was Chief Operating Officer at The Scripps Research Institute. He previously served as president and CEO of AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company developing new pain medications. Prior to AcelRx, he was President, Chief Operating Officer and general manager of the biotechnology company Tercica, Inc. (later sold to the Ipsen Group), where he was instrumental in the commercial launch of Dysport® (abobotulinumtoxinA) and Increlex™ (rhlGF-1). He also previously served as Executive Vice President of Commercial Operations at Kos Pharmaceuticals, Inc., where he oversaw the growth of Niaspan® (niacin extended-release) and the launch of Advicor® (niacin extended-release/lovastatin). He was Senior Vice President of Commercial Operations at Solvay and Vice President of Commercial Operations at Unimed, where he launched AndroGel® (testosterone gel). Mr. King received a B.Sc. in chemical engineering from the University of Surrey in the U.K. and an M.B.A. from the Manchester Business School in the U.K.
Dr. Patni joined Adamas as Chief Medical Officer in June 2015. Dr. Patni brings over 15 years of global drug development experience across multiple therapeutic areas as well as extensive knowledge of the drug approval process. Prior to joining Adamas, Dr. Patni served as Chief Development Officer at Ocera Therapeutics. Earlier in his career, he served as SVP (Chief Medical Officer) at Actelion US Pharmaceuticals, Executive Director/VP (Product Lifecycle Team Leader, Therapeutic Area Head) at Roche Pharmaceuticals, and Senior Medical Director (Development Team Leader) at Novartis and Pfizer Pharmaceuticals. Dr. Patni earned a B.S. from the City University of New York Sophie Davis School of Biomedical Education (accelerated BS/MD Program) and an M.D. from the Mount Sinai School of Medicine. He completed his residency and fellowship in internal medicine and cardiology at the Albert Einstein College of Medicine in New York, where he was also an attending physician.
Ms. Rhodes joined as our General Counsel and Corporate Secretary in April 2016. She previously served as General Counsel at Medivation, Inc., where she was responsible for Medivation’s legal matters and also served as Corporate Secretary and as Chief Compliance Officer. Before Medivation, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group and served as a global product lead for Pfizer Inc.’s primary care medicines. Prior to joining Pfizer, Ms. Rhodes was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP. She also served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.